RT Journal Article
SR Electronic
T1 FGF21 reflects a responsive adipose tissue-liver axis in both cardiometabolic burden and following metabolic surgery
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.31.24307065
DO 10.1101/2024.05.31.24307065
A1 Patt, Marie
A1 Karkossa, Isabel
A1 Krieg, Laura
A1 Massier, Lucas
A1 Makki, Kassem
A1 Tabei, Shirin
A1 Karlas, Thomas
A1 Dietrich, Arne
A1 Gericke, Martin
A1 Stumvoll, Michael
A1 Blüher, Matthias
A1 von Bergen, Martin
A1 Schubert, Kristin
A1 Kovacs, Peter
A1 Chakaroun, Rima M.
YR 2024
UL http://medrxiv.org/content/early/2024/06/04/2024.05.31.24307065.abstract
AB Objective This research aims to uncover the factors associated with circulating FGF21 levels in a cohort mimicking metabolic disease progression, examining its relationship with adipose tissue (AT) morphology and function. It also investigates FGF21 level changes post-metabolic surgery, predictive factors, and their links to metabolic adjustments.Design In this observational study, serum FGF21 was measured in 678 individuals cross-sectionally and longitudinally in 189 undergoing metabolic surgery. We explored links between FGF21, AT histology, cardiometabolic risk factors, weight loss, glucose metabolism changes using feature selection algorithms, univariate/multivariate models, and transcriptome/proteome network analyses in subcutaneous and visceral AT.Results FGF21 levels track closely with central adiposity, subclinical inflammation, insulin resistance, and cardiometabolic risk, with circulating leptin emerging as the top predictor. Visceral AT inflammation was associated with liver dysfunction and FGF21 elevation. Post-surgery, FGF21 peaked transitorily at 3 months and predicted fat mass loss at 12 months but not HOMA-IR improvements. Mediation analysis indicated an increased catabolic and AT-lipolytic state associated with higher liver enzyme and FGF21 levels (total effect 0.38, p<0.01; proportion mediation 32%, p<0.01). AT fibrosis was related to a blunted transitory FGF21 increase, and lower fat loss, and hence linked with a reduced surgical effect (FFA and visceral AT fibrosis: rho=-0.31, p=0.030; FFA and fat-mass loss: rho=0.17, p=0.020).Conclusion FGF21 reflects the liver’s metabolic response to AT characteristics in both central adiposity and after metabolic surgery, with its dynamics reflecting AT-liver crosstalk.Competing Interest StatementMB received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis and Sanofi. All other authors declare no conflict of interest.Funding StatementThis work was supported by the Deutsche Forschungsgemeinschaft (DFG German Research Foundation) through CRC 1052 project number 209933838 and by a junior research grant by the Medical Faculty, University of Leipzig, and by the Federal Ministry of Education and Research (BMBF) German FKZ: 01EO1501. Part of this work This work was supported by the European Union Seventh Framework Program for research, technological development and demonstration under grant agreement HEALTH-F4-2012-305312. RC was supported by a Walther-Benjamin fellowship from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the University of Leipzig's ethics committee (applications 017-12-23012012 and 047-13-28012013 [18,19]), with all participants providing written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://doi.org/10.5281/zenodo.10402000